Lung Biotechnology PBC

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Lung Biotechnology PBC sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Lung Biotechnology PBC: 7 sponsored US clinical trials, none currently recruiting.

Lung Biotechnology PBC sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Arterial Hypertension, with 1 trials.

Upper-quartile sponsor footprint

Lung Biotechnology PBC sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

TERMINATED Phase 3

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

NCT03657095
COMPLETED Phase 3

Beraprost-314d Added-on to Tyvaso® (BEAT)

NCT01908699
COMPLETED Phase 2

Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)

NCT00989963
COMPLETED Phase 2

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

NCT00990314
COMPLETED Phase 2

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

NCT00792571
COMPLETED Phase 2

A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients

NCT00781885
TERMINATED Phase 2

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00703339

Phase Distribution

PhaseTrial count
Phase 2 5
Phase 3 2

Therapeutic Areas

Pulmonary Arterial Hypertension 1

How the Lung Biotechnology PBC early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 5 completed (71%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Pulmonary Arterial Hypertension (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Lung Biotechnology PBC: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Lung Biotechnology PBC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Lung Biotechnology PBC3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Lung Biotechnology PBC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Lung Biotechnology PBC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Lung Biotechnology PBC page

7 registered trials is a research-attention snapshot, not an endorsement of Lung Biotechnology PBC or any single study.

  • None of Lung Biotechnology PBC's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Pulmonary Arterial Hypertension is the condition Lung Biotechnology PBC studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Arterial Hypertension trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Lung Biotechnology PBC pipeline card: 7 registered trials from official public datasets.Report a data error.